Applications of Cardiac Computed Tomography in the Cardio-Oncology Population

Michael E. Layoun, Eric H. Yang, Joerg Herrmann, Cezar A. Iliescu, Juan C. Lopez-Mattei, Kostas Marmagkiolis, Matthew J. Budoff, Maros Ferencik

Research output: Contribution to journalReview article

Abstract

The increased risk for cardiovascular events in aging cancer survivors and those undergoing certain chemotherapeutic treatments has raised concern for more rigorous screening and surveillance methods above that of the general population. At this time, there are limited guidelines for how to best manage this vulnerable cohort. Questions regarding timing of screening, choice of imaging modality and risk reduction strategies—especially in those patients with known atherosclerotic disease—remain to be elucidated. Over a decade of case series, retrospective studies and clinical trials have shed light on the evolving role of cardiac computed tomography (CT) in this population, of which there is a relative paucity of data regarding its potential utility in the specific cardio-oncology population. Focusing on ability of cardiac CT to evaluate multiple cardiac and vascular structures, provide diagnostic and prognostic information, as well as assist interventional and surgical colleagues in surgical/percutaneous valve replacement and revascularization strategies is the premise for this review.

Original languageEnglish (US)
Article number47
JournalCurrent treatment options in oncology
Volume20
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Tomography
Population
Aptitude
Risk Reduction Behavior
Surgical Instruments
Blood Vessels
Survivors
Retrospective Studies
Clinical Trials
Guidelines
Neoplasms
Therapeutics

Keywords

  • Cardiac computed tomography angiography
  • Cardiotoxicity
  • Coronary artery calcium score
  • Radiation-induced valvulopathy
  • Vasculotoxicity

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Layoun, M. E., Yang, E. H., Herrmann, J., Iliescu, C. A., Lopez-Mattei, J. C., Marmagkiolis, K., ... Ferencik, M. (2019). Applications of Cardiac Computed Tomography in the Cardio-Oncology Population. Current treatment options in oncology, 20(6), [47]. https://doi.org/10.1007/s11864-019-0645-2

Applications of Cardiac Computed Tomography in the Cardio-Oncology Population. / Layoun, Michael E.; Yang, Eric H.; Herrmann, Joerg; Iliescu, Cezar A.; Lopez-Mattei, Juan C.; Marmagkiolis, Kostas; Budoff, Matthew J.; Ferencik, Maros.

In: Current treatment options in oncology, Vol. 20, No. 6, 47, 01.06.2019.

Research output: Contribution to journalReview article

Layoun, ME, Yang, EH, Herrmann, J, Iliescu, CA, Lopez-Mattei, JC, Marmagkiolis, K, Budoff, MJ & Ferencik, M 2019, 'Applications of Cardiac Computed Tomography in the Cardio-Oncology Population', Current treatment options in oncology, vol. 20, no. 6, 47. https://doi.org/10.1007/s11864-019-0645-2
Layoun, Michael E. ; Yang, Eric H. ; Herrmann, Joerg ; Iliescu, Cezar A. ; Lopez-Mattei, Juan C. ; Marmagkiolis, Kostas ; Budoff, Matthew J. ; Ferencik, Maros. / Applications of Cardiac Computed Tomography in the Cardio-Oncology Population. In: Current treatment options in oncology. 2019 ; Vol. 20, No. 6.
@article{89dde30943994b0991f2df511426c609,
title = "Applications of Cardiac Computed Tomography in the Cardio-Oncology Population",
abstract = "The increased risk for cardiovascular events in aging cancer survivors and those undergoing certain chemotherapeutic treatments has raised concern for more rigorous screening and surveillance methods above that of the general population. At this time, there are limited guidelines for how to best manage this vulnerable cohort. Questions regarding timing of screening, choice of imaging modality and risk reduction strategies—especially in those patients with known atherosclerotic disease—remain to be elucidated. Over a decade of case series, retrospective studies and clinical trials have shed light on the evolving role of cardiac computed tomography (CT) in this population, of which there is a relative paucity of data regarding its potential utility in the specific cardio-oncology population. Focusing on ability of cardiac CT to evaluate multiple cardiac and vascular structures, provide diagnostic and prognostic information, as well as assist interventional and surgical colleagues in surgical/percutaneous valve replacement and revascularization strategies is the premise for this review.",
keywords = "Cardiac computed tomography angiography, Cardiotoxicity, Coronary artery calcium score, Radiation-induced valvulopathy, Vasculotoxicity",
author = "Layoun, {Michael E.} and Yang, {Eric H.} and Joerg Herrmann and Iliescu, {Cezar A.} and Lopez-Mattei, {Juan C.} and Kostas Marmagkiolis and Budoff, {Matthew J.} and Maros Ferencik",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s11864-019-0645-2",
language = "English (US)",
volume = "20",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Applications of Cardiac Computed Tomography in the Cardio-Oncology Population

AU - Layoun, Michael E.

AU - Yang, Eric H.

AU - Herrmann, Joerg

AU - Iliescu, Cezar A.

AU - Lopez-Mattei, Juan C.

AU - Marmagkiolis, Kostas

AU - Budoff, Matthew J.

AU - Ferencik, Maros

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The increased risk for cardiovascular events in aging cancer survivors and those undergoing certain chemotherapeutic treatments has raised concern for more rigorous screening and surveillance methods above that of the general population. At this time, there are limited guidelines for how to best manage this vulnerable cohort. Questions regarding timing of screening, choice of imaging modality and risk reduction strategies—especially in those patients with known atherosclerotic disease—remain to be elucidated. Over a decade of case series, retrospective studies and clinical trials have shed light on the evolving role of cardiac computed tomography (CT) in this population, of which there is a relative paucity of data regarding its potential utility in the specific cardio-oncology population. Focusing on ability of cardiac CT to evaluate multiple cardiac and vascular structures, provide diagnostic and prognostic information, as well as assist interventional and surgical colleagues in surgical/percutaneous valve replacement and revascularization strategies is the premise for this review.

AB - The increased risk for cardiovascular events in aging cancer survivors and those undergoing certain chemotherapeutic treatments has raised concern for more rigorous screening and surveillance methods above that of the general population. At this time, there are limited guidelines for how to best manage this vulnerable cohort. Questions regarding timing of screening, choice of imaging modality and risk reduction strategies—especially in those patients with known atherosclerotic disease—remain to be elucidated. Over a decade of case series, retrospective studies and clinical trials have shed light on the evolving role of cardiac computed tomography (CT) in this population, of which there is a relative paucity of data regarding its potential utility in the specific cardio-oncology population. Focusing on ability of cardiac CT to evaluate multiple cardiac and vascular structures, provide diagnostic and prognostic information, as well as assist interventional and surgical colleagues in surgical/percutaneous valve replacement and revascularization strategies is the premise for this review.

KW - Cardiac computed tomography angiography

KW - Cardiotoxicity

KW - Coronary artery calcium score

KW - Radiation-induced valvulopathy

KW - Vasculotoxicity

UR - http://www.scopus.com/inward/record.url?scp=85065410028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065410028&partnerID=8YFLogxK

U2 - 10.1007/s11864-019-0645-2

DO - 10.1007/s11864-019-0645-2

M3 - Review article

C2 - 31056717

AN - SCOPUS:85065410028

VL - 20

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 6

M1 - 47

ER -